Accessibility Menu
Edwards Lifesciences Stock Quote

Edwards Lifesciences (NYSE: EW)

$76.84
(1.1%)
+0.82
Price as of October 22, 2025, 4:00 p.m. ET

KEY DATA POINTS

Current Price
$76.84
Daily Change
(1.1%) +$0.82
Day's Range
$76.22 - $78.33
Previous Close
$76.84
Open
$76.8
Beta
0.88
Volume
11
Average Volume
4,487,529
Market Cap
45.1B
Market Cap / Employee
$76.84M
52wk Range
$64.89 - $83
Revenue
-
Gross Margin
0.78%
Dividend Yield
N/A
EPS
$1.46
CAPs Rating
-
Industry
Healthcare Equipment and Supplies

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

Edwards Lifesciences Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
EW+10.98%-4.44%-0.9%+5,488%
S&P+14.5%+93.32%+14.09%+340%

Edwards Lifesciences Company Info

Edwards Lifesciences Corp. engages in patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into four main areas: Transcatheter Aortic Valve Replacement, Transcatheter Mitral and Tricuspid Therapies, Surgical Structural Heart, and Critical Care. It operates through the following geographical segments: United States, Europe, Japan, and Rest of World. The company was founded by Miles Lowell Edwards in 1958 and is headquartered in Irvine, CA.

News & Analysis

The Fool has written over 100 articles on Edwards Lifesciences.

Financial Health

General

Q2 2025YOY Change
Revenue$1.53B10.6%
Gross Profit$1.18B8.2%
Gross Margin76.81%-1.7%
Market Cap$45.88B-17.6%
Market Cap / Employee$2.90M0.0%
Employees15.8K-20.2%
Net Income$335.90M-8.3%
EBITDA$458.10M13.3%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q2 2025YOY Change
Net Cash$3.27B98.7%
Accounts Receivable$697.00M-10.4%
Inventory1.1K11.4%

Liabilities

Q2 2025YOY Change
Long Term Debt$676.70M0.8%
Short Term Debt$25.90M20.5%

Ratios

Q2 2025YOY Change
Return On Assets11.98%-3.5%
Return On Invested Capital18.44%-2.2%

Cash Flow

Q2 2025YOY Change
Free Cash Flow$240.90M-15.8%
Operating Free Cash Flow$290.20M-21.9%

Valuation

MetricQ3 2024Q4 2024Q1 2025Q2 2025YoY Change
Price to Earnings46.6650.7848.4353.3940.44%
Price to Book5.344.574.274.53-42.10%
Price to Sales6.717.647.698.09-13.08%
Price to Tangible Book Value6.776.256.066.39-37.78%
Price to Free Cash Flow TTM76.45150.7967.2978.21-19.88%
Enterprise Value to EBITDA86.77103.3290.4693.17-30.99%
Free Cash Flow Yield1.3%0.7%1.5%1.3%24.82%
Return on Equity17.9%17.2%16.7%15.7%-26.41%
Total Debt$706.70M$700.00M$699.40M$702.60M1.39%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.